TY - STD TI - Singh RK, Singh DP, Tiwari SP, Mohapatra TM. Targeted therapies for cancer treatment. J Pharm Res. 2011;4(2):312–16. ID - ref1 ER - TY - JOUR AU - Gazdar, A. F. AU - Gao, B. AU - Minna, J. D. PY - 2010 DA - 2010// TI - Lung cancer cell lines: useless artifacts or invaluable tools for medical science? JO - Lung Cancer VL - 68 UR - https://doi.org/10.1016/j.lungcan.2009.12.005 DO - 10.1016/j.lungcan.2009.12.005 ID - Gazdar2010 ER - TY - JOUR AU - Wilding, J. L. AU - Bodmer, W. F. PY - 2014 DA - 2014// TI - Cancer cell lines for drug discovery and development JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-2971 DO - 10.1158/0008-5472.CAN-13-2971 ID - Wilding2014 ER - TY - JOUR AU - Long, D. L. PY - 2012 DA - 2012// TI - Tumor heterogeneity and personalized medicine JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMe1200656 DO - 10.1056/NEJMe1200656 ID - Long2012 ER - TY - JOUR AU - Oqino, S. AU - Galon, J. AU - Fuchs, C. S. AU - Dranoff, G. PY - 2011 DA - 2011// TI - Cancer immunology—analysis of host and tumor factors for personalized medicine JO - Nat Rev Clin Oncol VL - 8 UR - https://doi.org/10.1038/nrclinonc.2011.122 DO - 10.1038/nrclinonc.2011.122 ID - Oqino2011 ER - TY - JOUR AU - Garraway, L. A. AU - Janne, P. A. PY - 2012 DA - 2012// TI - Circumventing cancer drug resistance in the era of personalized medicine JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0012 DO - 10.1158/2159-8290.CD-12-0012 ID - Garraway2012 ER - TY - JOUR AU - Tuxe, I. V. AU - Jonson, L. AU - Santoni-Ruqiu, E. AU - Hasselby, J. P. AU - Nielsen, F. C. AU - Lassen, U. PY - 2014 DA - 2014// TI - Personalized oncology: genomic screening in phase 1 JO - APMIS VL - 122 UR - https://doi.org/10.1111/apm.12293 DO - 10.1111/apm.12293 ID - Tuxe2014 ER - TY - JOUR AU - Hayes, D. F. AU - Markus, H. S. AU - Leslie, R. D. AU - Topol, E. J. PY - 2014 DA - 2014// TI - Personalized medicine: risk prediction, targeted therapies and mobile health technology JO - BMC Med VL - 12 UR - https://doi.org/10.1186/1741-7015-12-37 DO - 10.1186/1741-7015-12-37 ID - Hayes2014 ER - TY - JOUR AU - Mahipal, A. AU - Kothari, N. AU - Gupta, S. PY - 2014 DA - 2014// TI - Epidermal growth factor receptor inhibitors: coming of age JO - Cancer Control VL - 21 ID - Mahipal2014 ER - TY - JOUR AU - Tonra, J. R. AU - Hicklin, D. J. PY - 2007 DA - 2007// TI - Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy JO - Immunol Invest VL - 36 UR - https://doi.org/10.1080/08820130600991794 DO - 10.1080/08820130600991794 ID - Tonra2007 ER - TY - JOUR AU - Fava, C. AU - Morotti, A. AU - Dogliotti, I. AU - Saglio, G. AU - Rege-cambrin, G. PY - 2015 DA - 2015// TI - Update on emerging treatment for chornic myeloid leukemia JO - Expert Opin Emerg Drugs VL - 20 UR - https://doi.org/10.1517/14728214.2015.1031217 DO - 10.1517/14728214.2015.1031217 ID - Fava2015 ER - TY - JOUR AU - Holohan, C. AU - Schaeybroeck, S. AU - Longley, D. B. AU - Johnston, P. G. PY - 2013 DA - 2013// TI - Cancer drug resistance: an evolving paradigm JO - Nat Rev Cancer VL - 13 UR - https://doi.org/10.1038/nrc3599 DO - 10.1038/nrc3599 ID - Holohan2013 ER - TY - STD TI - Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Ellrott K, Shmulevich I, Sander C, Stuart JM. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991;51(17):4575–80. ID - ref13 ER - TY - JOUR AU - Harwerth, I. M. AU - Wels, W. AU - Schlegel, J. AU - Muller, M. AU - Hynes, N. E. PY - 1993 DA - 1993// TI - Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth JO - Br J Cancer VL - 68 UR - https://doi.org/10.1038/bjc.1993.494 DO - 10.1038/bjc.1993.494 ID - Harwerth1993 ER - TY - JOUR AU - Mariani, G. AU - Gianni, L. PY - 2006 DA - 2006// TI - Adjuvant trastuzumab in early breast cancer JO - Ann Oncol VL - 17 UR - https://doi.org/10.1093/annonc/mdl237 DO - 10.1093/annonc/mdl237 ID - Mariani2006 ER - TY - JOUR AU - Yarden, Y. PY - 2001 DA - 2001// TI - Biology of HER2 and its importance in breast cancer JO - Oncology VL - 61 ID - Yarden2001 ER - TY - JOUR AU - Harari, D. AU - Yarden, Y. PY - 2000 DA - 2000// TI - Molecular mechanisms underlying ErbB2/HER2 action in breast cancer JO - Oncogene VL - 19 UR - https://doi.org/10.1038/sj.onc.1203973 DO - 10.1038/sj.onc.1203973 ID - Harari2000 ER - TY - JOUR AU - Fujimoto-Ouchi, K. AU - Sekiguchi, F. AU - Yasuno, H. AU - Moriya, Y. AU - Mori, K. AU - Tanaka, Y. PY - 2007 DA - 2007// TI - Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models JO - Cancer Chemother Pharmacol VL - 59 UR - https://doi.org/10.1007/s00280-006-0337-z DO - 10.1007/s00280-006-0337-z ID - Fujimoto-Ouchi2007 ER - TY - JOUR AU - Gong, S. J. AU - Jin, C. J. AU - Rha, S. Y. AU - Chung, H. C. PY - 2004 DA - 2004// TI - Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines JO - Cancer Lett VL - 214 UR - https://doi.org/10.1016/j.canlet.2004.04.029 DO - 10.1016/j.canlet.2004.04.029 ID - Gong2004 ER - TY - JOUR AU - Bang, Y. J. AU - Cutsem, E. AU - Feyereislova, A. AU - Chung, H. C. AU - Shen, L. AU - Sawaki, A. AU - Lordick, F. AU - Ohtsu, A. AU - Omuro, Y. AU - Satoh, T. PY - 2010 DA - 2010// TI - Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial JO - Lancet VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61121-X DO - 10.1016/S0140-6736(10)61121-X ID - Bang2010 ER - TY - JOUR AU - Bookman, M. A. AU - Darcy, K. M. AU - Clarke-Pearson, D. AU - Boothby, R. A. AU - Horowitz, I. R. PY - 2003 DA - 2003// TI - Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.10.104 DO - 10.1200/JCO.2003.10.104 ID - Bookman2003 ER - TY - JOUR AU - Nam, S. AU - Chang, H. R. AU - Kim, K. T. AU - Kook, M. C. AU - Hong, D. AU - Kwon, C. H. AU - Jung, H. R. AU - Park, H. S. AU - Powis, G. AU - Liang, H. PY - 2014 DA - 2014// TI - PATHOME: an algorithm for accurately detecting differentially expressed subpathways JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2014.80 DO - 10.1038/onc.2014.80 ID - Nam2014 ER - TY - STD TI - Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7. ID - ref23 ER - TY - STD TI - Goldman M, Craft B, Swatloski T, Cline M, Morozova O, Diekhans M, Haussler D, Zhu J. The UCSC cancer genomics browser: update 2015. Nucleic Acids Res. 2015;43(Database issue):D812–7. ID - ref24 ER - TY - STD TI - Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805. ID - ref25 ER - TY - STD TI - Starczynski J, Atkey N, Connelly Y, O’Grady T, Campbell FM, di Palma S, Wencyk P, Jasani B, Gandy M, Bartlett JM, Ukneqas. Ukneqas: HER2 gene amplification in breast cancer: a rogues’ gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol. 2012;137(4):595–605. ID - ref26 ER - TY - JOUR AU - Menard, S. AU - Fortis, S. AU - Castiglioni, F. AU - Agresti, R. AU - Balsari, A. PY - 2001 DA - 2001// TI - HER2 as a prognostic factor in breast cancer JO - Oncology VL - 61 ID - Menard2001 ER - TY - STD TI - Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8(1):103–12. ID - ref28 ER - TY - JOUR AU - Grabsch, H. AU - Sivakumar, S. AU - Gray, S. AU - Gabbert, H. E. AU - Muller, W. PY - 2010 DA - 2010// TI - HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series JO - Cell Oncol VL - 32 ID - Grabsch2010 ER - TY - JOUR AU - Hechtman, J. F. AU - Polydorides, A. D. PY - 2012 DA - 2012// TI - HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications JO - Arch Pathol Lab Med VL - 136 UR - https://doi.org/10.5858/arpa.2011-0168-RS DO - 10.5858/arpa.2011-0168-RS ID - Hechtman2012 ER - TY - STD TI - Bilous M, Osamura RY, Ruschoff J, van de Vijver M, Hanna W, Penault-Llorca F, Roche P. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2010;41(2):304–5. author reply 5–6. ID - ref31 ER - TY - STD TI - Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Shawver LK. The cancer genome atlas Pan-cancer analysis project. Nat Genet. 2013;45(10):1113–20. ID - ref32 ER - TY - JOUR AU - Gao, J. AU - Aksoy, B. A. AU - Dogrusoz, U. AU - Dresdner, G. AU - Gross, B. AU - Sumer, S. O. AU - Sun, Y. AU - Jacobsen, A. AU - Sinha, R. AU - Larsson, E. PY - 2013 DA - 2013// TI - Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal JO - Sci Signal VL - 6 UR - https://doi.org/10.1126/scisignal.2004088 DO - 10.1126/scisignal.2004088 ID - Gao2013 ER - TY - JOUR AU - Hiyama, T. AU - Tanaka, S. AU - Yoshihara, M. AU - Sasao, S. AU - Kose, K. AU - Shima, H. AU - Tuncel, H. AU - Ueno, Y. AU - Ito, M. AU - Kitadai, Y. PY - 2004 DA - 2004// TI - Chromosomal and microsatellite instability in sporadic gastric cancer JO - J Gastroenterol Hepatol VL - 19 UR - https://doi.org/10.1111/j.1440-1746.2004.03369.x DO - 10.1111/j.1440-1746.2004.03369.x ID - Hiyama2004 ER - TY - JOUR AU - Barretina, J. AU - Caponigro, G. AU - Stransky, N. AU - Venkatesan, K. AU - Margolin, A. A. AU - Kim, S. AU - Wilson, C. J. AU - Lehar, J. AU - Kryukov, G. V. AU - Sonkin, D. PY - 2012 DA - 2012// TI - The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity JO - Nature VL - 483 UR - https://doi.org/10.1038/nature11003 DO - 10.1038/nature11003 ID - Barretina2012 ER - TY - JOUR AU - Naef, M. AU - Yokoyama, M. AU - Friess, H. AU - Buchler, M. W. AU - Korc, M. PY - 1996 DA - 1996// TI - Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma JO - Int J Cancer VL - 66 UR - https://doi.org/3.0.CO;2-1 DO - 3.0.CO;2-1 ID - Naef1996 ER - TY - JOUR AU - Lauren, P. PY - 1965 DA - 1965// TI - The Two histological main types of gastric carcinoma: diffuse and So-called intestinal-type carcinoma. An attempt at a histo-clinical classification JO - Acta Pathol Microbiol Scand VL - 64 ID - Lauren1965 ER - TY - JOUR AU - Ku, J. L. AU - Kim, K. H. AU - Choi, J. S. AU - Kim, S. H. AU - Shin, Y. K. AU - Chang, H. J. AU - Bae, J. M. AU - Kim, Y. W. AU - Lee, J. H. AU - Yang, H. K. PY - 2012 DA - 2012// TI - Establishment and characterization of six human gastric carcinoma cell lines, including one naturally infected with Epstein-Barr virus JO - Cell Oncol (Dordr) VL - 35 UR - https://doi.org/10.1007/s13402-012-0073-9 DO - 10.1007/s13402-012-0073-9 ID - Ku2012 ER - TY - JOUR AU - Yokozaki, H. PY - 2000 DA - 2000// TI - Molecular characteristics of eight gastric cancer cell lines established in Japan JO - Pathol Int VL - 50 UR - https://doi.org/10.1046/j.1440-1827.2000.01117.x DO - 10.1046/j.1440-1827.2000.01117.x ID - Yokozaki2000 ER - TY - STD TI - Terasawa T, Nishida H, Kato K, Miyashiro I, Yoshikawa T, Takaku R, Hamashima C. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS ONE. 2014;9(10), e109783. ID - ref40 ER - TY - JOUR AU - Kao, J. AU - Salari, K. AU - Bocanegra, M. AU - Choi, Y. L. AU - Girard, L. AU - Gandhi, J. AU - Kwei, K. A. AU - Hernandez-Boussard, T. AU - Wang, P. AU - Gazdar, A. F. PY - 2009 DA - 2009// TI - Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery JO - PLoS ONE VL - 4 UR - https://doi.org/10.1371/journal.pone.0006146 DO - 10.1371/journal.pone.0006146 ID - Kao2009 ER - TY - JOUR AU - Neve, R. M. AU - Chin, K. AU - Fridlyand, J. AU - Yeh, J. AU - Baehner, F. L. AU - Fevr, T. AU - Clark, L. AU - Bayani, N. AU - Coppe, J. P. AU - Tong, F. PY - 2006 DA - 2006// TI - A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes JO - Cancer Cell VL - 10 UR - https://doi.org/10.1016/j.ccr.2006.10.008 DO - 10.1016/j.ccr.2006.10.008 ID - Neve2006 ER - TY - STD TI - Cardano M, Diaferia GR, Falavigna M, Spinelli CC, Sessa F, DeBlasio P, Biunno I. Cell and tissue microarray technologies for protein and nucleic acid expression profiling. J Histochem Cytochem. 2013;61(2):116–24. ID - ref43 ER - TY - JOUR AU - Gong, J. AU - Morishita, A. AU - Kurokohchi, K. AU - Tani, J. AU - Kato, K. AU - Miyoshi, H. AU - Inoue, H. AU - Kobayashi, M. AU - Liu, S. AU - Murota, M. PY - 2010 DA - 2010// TI - Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer JO - Int J Oncol VL - 36 ID - Gong2010 ER - TY - JOUR AU - Boku, N. PY - 2014 DA - 2014// TI - HER2-positive gastric cancer JO - Gastric Cancer VL - 17 UR - https://doi.org/10.1007/s10120-013-0252-z DO - 10.1007/s10120-013-0252-z ID - Boku2014 ER - TY - JOUR AU - Kim, Y. H. AU - Liang, H. AU - Liu, X. AU - Lee, J. S. AU - Cho, J. Y. AU - Cheong, J. H. AU - Kim, H. AU - Li, M. AU - Downey, T. J. AU - Dyer, M. D. PY - 2012 DA - 2012// TI - AMPKalpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3870 DO - 10.1158/0008-5472.CAN-11-3870 ID - Kim2012 ER - TY - STD TI - Chang HR, Nam S, Kook MC, Kim KT, Liu X, Yao H, Jung HR, Lemos R, Jr., Seo HH, Park HS, et al. HNF4alpha is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut. 2014. ID - ref47 ER - TY - STD TI - Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol. 2012;2012568567. ID - ref48 ER - TY - JOUR AU - Richmond, A. AU - Su, Y. PY - 2008 DA - 2008// TI - Mouse xenograft models vs GEM models for human cancer therapeutics JO - Dis Model Mech VL - 1 UR - https://doi.org/10.1242/dmm.000976 DO - 10.1242/dmm.000976 ID - Richmond2008 ER - TY - JOUR AU - Garcia-Garcia, C. AU - Ibrahim, Y. H. AU - Serra, V. AU - Calvo, M. T. AU - Guzman, M. AU - Grueso, J. AU - Aura, C. AU - Perez, J. AU - Jessen, K. AU - Liu, Y. PY - 2012 DA - 2012// TI - Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-2750 DO - 10.1158/1078-0432.CCR-11-2750 ID - Garcia-Garcia2012 ER - TY - STD TI - Daniele S, Costa B, Zappelli E, Da Pozzo E, Sestito S, Nesi G, Campiglia P, Marinelli L, Novellino E, Rapposelli S, Martini C. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep. 2015;59956. ID - ref51 ER - TY - JOUR AU - Xu, L. AU - Kikuchi, E. AU - Xu, C. AU - Ebi, H. AU - Ercan, D. AU - Cheng, K. A. AU - Padera, R. AU - Engelman, J. A. AU - Janne, P. A. AU - Shapiro, G. I. PY - 2012 DA - 2012// TI - Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3720 DO - 10.1158/0008-5472.CAN-11-3720 ID - Xu2012 ER - TY - STD TI - Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res. 2004;10(7):2512–24. ID - ref53 ER -